Investors sold shares of Abbott Laboratories (NYSE:ABT) on strength during trading on Wednesday. $90.28 million flowed into the stock on the tick-up and $122.97 million flowed out of the stock on the tick-down, for a money net flow of $32.69 million out of the stock. Of all stocks tracked, Abbott Laboratories had the 19th highest net out-flow for the day. Abbott Laboratories traded up $0.71 for the day and closed at $55.77
A number of equities research analysts have recently weighed in on ABT shares. Royal Bank Of Canada reissued a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a report on Tuesday, October 3rd. Jefferies Group LLC restated a “buy” rating and issued a $58.00 price target on shares of Abbott Laboratories in a research report on Thursday, June 29th. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 price target (up previously from $47.50) on shares of Abbott Laboratories in a research report on Friday, June 30th. Finally, Cowen and Company restated an “outperform” rating and issued a $55.00 price target (up previously from $48.00) on shares of Abbott Laboratories in a research report on Friday, July 14th. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $54.94.
The stock’s 50-day moving average price is $52.59 and its 200 day moving average price is $48.17. The firm has a market capitalization of $96.90 billion, a PE ratio of 78.11 and a beta of 1.06.
Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The company’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 EPS. Analysts expect that Abbott Laboratories will post $2.50 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.90%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s payout ratio is 149.30%.
In related news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $52.95, for a total value of $3,307,257.00. Following the completion of the sale, the insider now owns 113,426 shares of the company’s stock, valued at $6,005,906.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jaime Contreras sold 52,700 shares of Abbott Laboratories stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $51.97, for a total value of $2,738,819.00. Following the completion of the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. In the last three months, insiders sold 333,310 shares of company stock valued at $16,857,255. Corporate insiders own 0.76% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of ABT. Capital Research Global Investors grew its holdings in shares of Abbott Laboratories by 45.7% in the second quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after acquiring an additional 14,918,038 shares during the period. State Street Corp grew its holdings in shares of Abbott Laboratories by 18.9% in the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock worth $3,574,987,000 after acquiring an additional 12,806,535 shares during the period. Boston Partners grew its holdings in shares of Abbott Laboratories by 5,663.7% in the first quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock worth $364,696,000 after acquiring an additional 8,069,557 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Abbott Laboratories by 3,373.9% in the second quarter. Janus Henderson Group PLC now owns 7,874,473 shares of the healthcare product maker’s stock worth $382,779,000 after acquiring an additional 7,647,798 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Abbott Laboratories by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock worth $1,500,920,000 after acquiring an additional 3,344,508 shares during the period. 71.45% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Traders Sell Abbott Laboratories (ABT) on Strength (ABT)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/2968942/traders-sell-abbott-laboratories-abt-on-strength-abt.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.